December 10, 2024
Title: MASLD/MASH: Clinical and Economic Findings from 40-year Follow-Up Data
Tuesday, December 10, 2024
9:00AM EST |1:00PM UTC | 3:00PM CEST
Click here for time zone conversion
Description:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is initially characterized by simple steatosis but can progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by the histological observation of steatosis, hepatocellular ballooning, and inflammation.
Patients with MASLD are at risk of cardiovascular events and hepatic manifestations, and have an elevated mortality risk. Several European and US studies have demonstrated that healthcare costs for patients with MASLD are higher than those for age-matched controls and that patients with more advanced MASLD (e.g. MASH) consistently incur higher direct and indirect healthcare costs and have greater healthcare resource utilization (HCRU) than those at a less advanced stage of MASLD.
Given the chronic nature of MASLD, it is vital to understand the drivers for long-term clinical outcomes, high costs and HCRU to help inform disease awareness, identify at-risk patients early and initiate treatment to prevent disease progression and minimize clinical and economic burden.
In this webinar, we explore the findings of the BRIDGE-MASH study, assessing clinical and economic outcomes in a cohort of patients with an unprecedented follow-up period of more than 40 years.
Learning Objectives:
1. Gain an understanding of the clinical, HCRU and cost burden of MASLD and MASH.
2. Recognize the patient characteristics that increase the risk of long-term clinical outcomes and high costs/HCRU.
3. Gain an understanding of how clinical outcomes and costs could be reduced through timely diagnosis and improved access to treatment.
Moderator:
Riku Ota, MPH, Global Payer Evidence Lead, Novo Nordisk A/S, Søborg, Copenhagen, Denmark
Speakers:
Hannes Hagström, MD, Professor, Karolinska Institutet, Stockholm, Sweden
Ying Shang, MD, Assistant Professor, Karolinska Institutet, Stockholm, Sweden
Emilie Toresson Grip, MSc, Director, Head of RWE and Data Analytics, Quantify Research, Stockholm, Sweden
Brought to you by: Novo Nordisk
Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar. Reservations are on a first-come, first-served basis.